Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Description: Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Summary

The publisher has released its new PharmaPoint Drug Evaluation report, "Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

GSK's Bosatria (mepolizumab) is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. It was originally developed for the treatment of hypereosinophilic syndrome, but GSK withdrew its authorization application after the CHMP determined that the data were insufficient to conclude whether there is a positive benefit-risk balance for Bosatria in asthma (GSK, press release, July 29, 2009). GSK boasts multibillion dollar sales for its blockbuster, Advair/Seretide, but Bosatria is not expected to reach this status, since it will only be used in a limited number of refractory patients.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Bosatria including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Bosatria for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Bosatria performance
- Obtain sales forecast for Bosatria from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
Table 6: Leading Treatments for Asthma, 2014
Table 7: Unmet Need and Opportunity in Asthma
Table 8: Asthma - Late Stage Pipeline, 2014
Table 9: Product Profile - Bosatria
Table 10: Efficacy of Bosatria Versus Placebo
Table 11: Bosatria’s Safety Profile
Table 12: Bosatria SWOT Analysis, 2012
Table 13: Global Sales Forecast ($) for Bosatria, 2013-2023
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Stepwise Disease Management Approach for Asthma in Adults
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023
- Web Address: http://www.researchandmarkets.com/reports/2989104/
- Office Code: SCD22DUD

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>□</td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□</td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>□ Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □</td>
</tr>
<tr>
<td>First Name:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>___________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World